Journal of Hepato-Biliary-Pancreatic Surgery

, Volume 11, Issue 6, pp 430–433

Cholangiocarcinoma in association with Thorotrast exposure

  • Andrew X. Zhu
  • Gregory Y. Lauwers
  • Kenneth K. Tanabe
Article

DOI: 10.1007/s00534-004-0924-5

Cite this article as:
Zhu, A., Lauwers, G. & Tanabe, K. J Hepatobiliary Pancreat Surg (2004) 11: 430. doi:10.1007/s00534-004-0924-5

Abstract

Thorotrast is a colloidal suspension of thorium dioxide that was used as an intravascular contrast agent until the 1950’s. It is retained by the reticuloendothelial system, and because it emits densely ionizing radioactivity thorium dioxide it is carcinogenic. Two patients with prior thorium dioxide exposure diagnosed with cholangiocarcinoma and recently treated at the Massachusetts General Hospital are presented. Radiology, treatment, pathologic findings, and relevant literature are discussed.

Key words

Thorotrast Cholangiocarcinoma 

Copyright information

© Springer-Verlag Tokyo 2004

Authors and Affiliations

  • Andrew X. Zhu
    • 1
    • 4
  • Gregory Y. Lauwers
    • 2
    • 4
  • Kenneth K. Tanabe
    • 3
    • 4
  1. 1.Division of Hematology/OncologyMassachusetts General HospitalBostonUSA
  2. 2.Department of PathologyMassachusetts General HospitalBostonUSA
  3. 3.Division of Surgical OncologyMassachusetts General HospitalBostonUSA
  4. 4.Havard Medical SchoolBostonUSA

Personalised recommendations